RxDoctor Payments Data

Varun Puducheri, MD

Internal Medicine · Huntsville, ALNPI 1700083482

Payments from drug & device makers

$987in general payments, 2019–2025

Across 45 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$198
  • Axsome Therapeutics, Inc.$187
  • Novo Nordisk$146
  • Amgen$111
  • Astellas Pharma US Inc$93
  • AstraZeneca$52
  • plus $200 from 6 others

What the payments were for

  • Food & beverage$94295%
  • Education$455%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$987 in reported general payments places this provider in the 60th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$240,105
Medicare patients
239
Services billed
2,587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide72$125,162
OzempicSemaglutide101$98,711
JanuviaSitagliptin Phosphate87$93,859
EliquisApixaban63$77,473
JardianceEmpagliflozin43$55,694
RybelsusSemaglutide23$44,034
ProliaDenosumab16$26,831
Tresiba Flextouch U-100Insulin Degludec18$24,076
XareltoRivaroxaban18$20,238
TrulicityDulaglutide17$16,523
Pravastatin Sodium181$3,569
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$3,246
Atorvastatin Calcium265$3,209
Albuterol Sulfate HfaAlbuterol Sulfate75$3,136
SynthroidLevothyroxine Sodium40$3,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$146$142,745124 claims
Lilly USA, LLCMounjaro, Trulicity$198$141,68589 claims
PfizerEliquis$40$77,47363 claims
Boehringer IngelheimJardiance$16$55,69443 claims
AmgenProlia$111$26,83116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →